약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 3.

Table. 3. Spending trends of non-RSA listed high-priced medicines by drug characteristics (unit: 1,000,000 KRW)
Category 2010 2012 2014 2016 2018 2020 2021 (%) CAGR
Total non-RSA drugs 388,347 441,905 508,714 528,636 547,330 595,991 653,892 (100.0%) 4.9%1)
3.7%2)
Cost per patient (million KRW/patient)
Low (10~50) 244,250 295,605 282,517 398,259 358,052 372,502 427,707 (65.4%) 5.2%
Middle (50~100) 100,975 74,963 83,733 36,268 60,398 74,019 76,003 (11.6%) -2.5%
High (100~300) 24,660 36,370 64,549 72,192 64,179 86,096 89,921 (13.8%) 12.5%
Extra high (300+) 18,462 34,966 77,916 21,916 64,700 63,373 60,261 (9.2%) 11.4%
Supplier type
International 289,683 398,459 433,166 468,978 468,265 510,431 564,516 (86.3%) 6.3%
Domestic 98,664 43,446 75,548 59,658 79,065 85,559 89,377 (13.7%) -0.9%
ATC category
A10A 25
A16A 23,814 46,276 60,680 75,365 79,411 91,853 106,184 (16.2%) 14.6%
B01A 370 602 1,371 2,151 4,784 7,465 (1.1%) 39.6%
B02B 121,423 127,213 156,958 170,065 188,856 206,656 204,472 (31.3%) 4.9%
B05D 16,087 8,753
C02K 8,245 11,425 14,222 2,871 12,453 19,082 21,634 (3.3%) 9.2%
H01C 7,542 9,068 10,342 4,875 11,808 13,140 7,304 (1.1%) -0.3%
J02A 10,930
J04A 3,260 7,028 7,817 11,944 (1.8%) 29.7%
J05A 109,743 53,915 44,941 49,199 (7.5%) -14.8%
J06B 47,001
L01A . 822 1,375 2,256 2,664 2,894
L01B 7,561 10,130 14,810 15,530 18,899 5,763
L01E 95,831 115,372 96,044 135,964 151,170 164,595 170,681 (26.1%) 5.4%
L01F 42,372 85,371 93,679 1,101 815 1,636 18,716 (2.9%) -7.2%
L01X 11,865 18,676 22,814 1,181 1,154 2,196 1,842 (0.3%) -15.6%
L03A 6,606 8,207 8,587 3,825 7,365 5,698 6,736 (1.0%) 0.2%
L04A 221 17,170 1,229 9,642 23,604 46,792 (7.2%) 81.3%
N03A 503 1,186
S01G 123 218 (0.0%)
V09I 706 (0.1%)

1) CAGR was calculated from 2010 to 2021.

2) CAGR was calculated from 2014 to 2021 to compare RSA listed drugs.

Yakhak Hoeji 2023;67:388-97 https://doi.org/10.17480/psk.2023.67.6.388
© 2023 Yakhak Hoeji